Diazabicyclooctanones as inhibitors of serine β-lactamases
US12378244B2 · kind B2 · utility
0Cited by
1References
29Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 15, 2023 |
| Grant date | Aug 5, 2025 |
| Priority date | — |
| Expiry date | Nov 15, 2043 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to a compound which is a diazabicyclooctanone of Formula (I) or a pharmaceutically acceptable salt thereof: wherein R is as defined herein. The compounds are useful in the treatment of bacterial infection, in particular they are useful in reducing bacterial resistance to antibiotics. They are also useful in the treatment of bacteria which express serine-β-lactamase enzymes, in combination with antibiotics.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.